Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 9008 results

  1. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

    Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.

  2. Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer (TA1110)

    Evidence-based recommendations on abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.

  3. Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

    NICE is unable to recommend panitumumab with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults. This is because Amgen did not provide an evidence submission.

    Sections for TA240

  4. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block (TA88)

    Evidence-based recommendations on using dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome or atrioventricular block.

  5. Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) (TA923)

    NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA923

  6. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.

  7. AHEAD implants for external ear prosthesis

    Topic prioritisation

  8. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

    Topic prioritisation

  9. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

  10. Secukinumab biosimilar for treating plaque psoriasis [TSID11992]

    Topic prioritisation

  11. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years [TSID11959]

    Topic prioritisation

  12. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]

    Topic prioritisation

  13. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]

    Topic prioritisation